Paragraph 41A Transitional provision in relation to global marketing authorisations under the 2001 DirectiveF1

Where a relevant medicinal product is subject to a global marketing authorisation as described in Article 6 of the 2001 Directive before IP completion day, a paediatric investigation plan does not need to be carried out in relation to that product.